BIOMAT Database Logo BIOMAT Database Logo

Prophylaxis of antipsychotic drug-induced extrapyramidal syndromes. 1991

G A Keepers

UI MeSH Term Description Entries
D009459 Neuroleptic Malignant Syndrome A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72) Neuroleptic-Induced Neuroleptic Malignant Syndrome,Neuroleptic-Malignant Syndrome, Neuroleptic Induced,NMS (Neuroleptic Malignant Syndrome),NMSs (Neuroleptic Malignant Syndrome),Neuroleptic Induced Neuroleptic Malignant Syndrome,Neuroleptic Malignant Syndrome, Neuroleptic Induced,Neuroleptic Malignant Syndromes,Syndrome, Neuroleptic Malignant,Syndromes, Neuroleptic Malignant
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G A Keepers
Drug-induced extrapyramidal syndromes.
October 1970, Journal of the Royal College of Physicians of London,
G A Keepers
Myasthenic crisis may mimic antipsychotic-induced extrapyramidal syndromes.
January 2011, The Journal of neuropsychiatry and clinical neurosciences,
G A Keepers
Tardive drug-induced extrapyramidal syndromes.
September 2000, Pharmacopsychiatry,
G A Keepers
Acute drug-induced extrapyramidal syndromes.
September 1973, The Practitioner,
G A Keepers
Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.
July 2001, European journal of clinical pharmacology,
G A Keepers
Antipsychotic-induced extrapyramidal syndromes in psychiatric practice: a case-control study.
August 2005, Pharmacy world & science : PWS,
G A Keepers
Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
January 1991, Schizophrenia research,
G A Keepers
Drug-Induced Extrapyramidal Syndromes: Implications for Contemporary Practice.
September 2016, The Psychiatric clinics of North America,
G A Keepers
Detecting biomarkers associated with antipsychotic-induced extrapyramidal syndromes by using machine learning techniques.
February 2023, Journal of psychiatric research,
G A Keepers
Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.
April 2002, Pharmacogenetics,
Copied contents to your clipboard!